Cellebrite DI (CLBT) Cost of Revenue (2020 - 2026)

Over the twelve months ended Jun 30, 2026, Cellebrite DI's Cost of Revenue came in at $87.63 million, up 28.4% year-over-year; for the year ended Dec 31, 2025, it came in at $75.17 million, up 20.1% from the prior year.

• Cost of Revenue has increased for six consecutive years, with a five-year compound annual growth rate of 14.7% (years ended Dec 2020 to Dec 2025).
• By year, Cost of Revenue came in at $62.59 million in the year ended Dec 31, 2024 (+17.6%), $53.23 million in the year ended Dec 31, 2023 (+4.9%), $50.75 million in the year ended Dec 31, 2022 (+19.2%) and $42.56 million in the year ended Dec 31, 2021 (+12.3%).
• The figure for the quarter ended Jun 30, 2026 ranks as the highest quarterly Cost of Revenue in data going back to the quarter ended Sep 30, 2020.
• Year over year, Cost of Revenue has now increased in each of the last 11 quarters, with growth averaging 24.1% over the last eight quarters.
• The high point for year-over-year Cost of Revenue in five years was the quarter ended Jun 30, 2026 (growth of 42.6%); the low point was the quarter ended Sep 30, 2023 (a decline of 11.4%).
• Per Business Quant data, the three quarters before the quarter ended Jun 30, 2026 came in at $22.42 million (quarter ended Mar 31, 2026), $19.69 million (quarter ended Dec 31, 2025) and $20.31 million (quarter ended Sep 30, 2025).